Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159190 | 0.93 | MAPT (0.62) | MAPTTDP1PDE4DTUBB1MCL1 | |
| SCHEMBL29997568 | 0.89 | TDP1 (0.44) | MAPTTDP1PDE4DTUBB1MCL1 | |
| SCHEMBL2202238 | 0.89 | TDP1 (0.44) | MAPTTDP1PDE4DTUBB1MCL1 | |
| Pyridine SCHEMBL27735324 | 0.87 | CYP1A1 (0.52) | MAPTTDP1PDE4DMEN1KMT2A | |
| SCHEMBL11671059 | 0.85 | MAPT (0.47) | MAPTTDP1PDE4DTUBB1ALDH1A1 | |
| SCHEMBL7032033 | 0.85 | MAPT (0.51) | MAPTTDP1PDE4DMCL1MEN1 | |
| SCHEMBL7478982 | 0.85 | MAPT (0.51) | MAPTTDP1PDE4DTUBB1MCL1 | |
| SCHEMBL10703741 | 0.84 | PDE4D (0.47) | MAPTTDP1PDE4DMEN1KMT2A | |
| SCHEMBL9726919 | 0.83 | MAPT (0.58) | MAPTTDP1PDE4DTUBB1MCL1 | |
| SCHEMBL4299425 | 0.83 | MAPT (0.48) | MAPTTDP1PDE4DTUBB1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631632-A | Dihydroxylactam-based polymers, compositions thereof and uses thereof | ISP投资有限公司 | 2021-11-09 | — | — | CN | claimed |
| CN-110483550-A | One kind derivative of rutaecarpin containing trimethoxyphenyl and its application | UNIV SOUTH CHINA | 2019-11-22 | — | — | CN | claimed |
| CN-107163011-B | 3- (3,4,5- trimethoxybenzoyl)-benzofurans Antitubulin and its preparation method and application | 上海应用技术大学 | 2019-10-01 | — | — | CN | claimed |
| CN-107163011-A | 3 (3,4,5 trimethoxybenzoyl) benzofurans Antitubulins and its production and use | 上海应用技术大学 | 2017-09-15 | — | — | CN | claimed |
| CN-102531888-B | Chemical synthesis method of 3,4,5-trimethoxy benzoyl chloride | UNIV WENZHOU | 2014-05-14 | — | — | CN | claimed |
| CN-102531888-A | Chemical synthesis method of 3,4,5-trimethoxy benzoyl chloride | UNIV WENZHOU | 2012-07-04 | — | — | CN | claimed |
| CN-102153536-A | Mangiferin aglycon derivative, as well as preparation method and application of the mangiferin aglycon derivative | SHANGHAI CHANGZHENG HOSPITAL | 2011-08-17 | — | — | CN | claimed |
| US-20100279971-A1 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | UNIVERSIDAD DE MURCIA (ES) | 2010-11-04 | — | — | US | claimed |
| EP-2231151-A2 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | Universidad de Murcia (ES) | 2010-09-29 | — | — | EP | claimed |
| WO-2009081275-A2 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | UNIVERSIDAD DE MURCIA (ES) | 2009-07-02 | — | — | WO | claimed |
| CN-101081849-A | Technique for synthesizing ground shepping | CHANGCHUN MAILING BIOENGINEERI (CN) | 2007-12-05 | — | — | CN | claimed |
| CN-1974554-A | Cyclin imide peptidyl metalloprotease inhibitor and its application | UNIV SHANDONG (CN) | 2007-06-06 | — | — | CN | claimed |
| US-4758666-A | Process for the preparation of an apovincaminol derivative | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1988-07-19 | — | — | US | claimed |
| US-4104278-A | Process for the production of compounds with antiphlogistic activity | TROPONWERKE DINKLAGE & CO. (DE) | 1978-08-01 | — | — | US | claimed |
| JP-4368379-A | — | — | None | — | — | JP | disclosed |
| EP-4683923-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2026-01-28 | — | — | EP | disclosed |
| US-20240400581-A1 | Process for Preparing a Macrocyclic Compound Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-12-05 | — | — | US | disclosed |
| US-4044012-A | Indolo-quinolizidine derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-08-23 | — | — | US | disclosed |
| US-4036841-A | VASODILATORS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-07-19 | — | — | US | disclosed |
| US-3962326-A | CARBOXYLIC ACID OR ANHYDRIDE, PHOSGENE, TRISUBSTITUTED PHOSPHINE OXIDE OR SULFIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400581-A1 | Process for Preparing a Macrocyclic Compound Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | MAPT 4812/4885TDP1 1164/4885PDE4D 3693/4885 |
| US-20100279971-A1 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | RECQL, MTX1, RRM2B | MAPT 4369/4885TDP1 2263/4885PDE4D 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.